Finance

Lists
SNDX:NASDAQ
Syndax Pharmaceuticals Inc
$9.45
-0.94%
(-0.090) 1D
Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SNDX...
Open
$9.72
High
$9.85
Low
$9.11
Mkt. cap
850.77M
Avg. vol.
3.49M
Volume
3.18M
52-wk high
$25.59
52-wk low
$9.11
EPS
-$2.37
Beta
0.48
Shares outstanding
90.03M
No. of employees
298
Open
$9.72
High
$9.85
Low
$9.11
Mkt. cap
850.77M
Avg. vol.
3.49M
Volume
3.18M
52-wk high
$25.59
52-wk low
$9.11
EPS
-$2.37
Beta
0.48
Shares outstanding
90.03M
No. of employees
298
News stories
From web sources and news partners
About Syndax Pharmaceuticals Inc
CEO-
Employees298
Founded2005
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitesyndax.com
Analyst ratings
Based on 7 analysts giving stock ratings to SNDX in the past 3 months
Strong buy
Buy
6
Hold
1
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for SNDX in the last 3 months.
Highest
Current $9.45
$57.00 (+503.17%)
Average
$37.00 (+291.53%)
Lowest
$23.00 (+143.39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
B. Riley Securities
Buy
Initiated
$33.00
+249.2%
11/04/2026
Stephen Willey
Stifel Nicolaus
Buy
Reiterated
$40.00
+323.3%
11/05/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$36.00
+281%
11/05/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$57.00
+503.2%
11/02/2026
Etzer Darout
Barclays
Buy
Maintained
$37.00
+291.5%
11/03/2026
David Dai
UBS
Hold
Maintained
$33.00
+249.2%
11/02/2026
Jason Zemansky
Bank of America Securities
Buy
Reiterated
$23.00
+143.4%
11/02/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$40.00
+323.3%
08/11/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
08/04/2026
Bradley Canino
Guggenheim
Buy
Maintained
$31.00
+228%
07/14/2026
Corinne Johnson
Goldman Sachs
Buy
Maintained
$34.00
+259.8%
07/14/2026
Faisal Khurshid
Jefferies
Buy
Maintained
$37.00
+291.5%
05/01/2026
Unknown Analyst
Jefferies
Buy
Maintained
$40.00
+323.3%
03/30/2026
Unknown Analyst
Mizuho Securities
Buy
Maintained
$43.00
+355%
03/30/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$43.00
+355%
03/30/2026
Last report
Nov 2, 2026
Fiscal period
Q3 2026
-$0.55 / -$0.48
-13.69%miss
Revenue / Est. (USD)
83.30M / 81.81M
+1.82%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
68.73M
64.86M
72.79M
83.30M
Cost of goods sold
81.35M
61.48M
71.24M
81.48M
Cost of revenue
81.35M
61.48M
71.24M
81.48M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
49.93M
37.59M
41.54M
43.72M
Operating expense
49.93M
37.59M
41.54M
43.72M
Total operating expenses
131.28M
99.07M
112.78M
125.19M
Operating income
-62.55M
-34.20M
-40.00M
-41.90M
Other non operating income
-201.00K
-186.00K
-438.00K
-153.00K
EBT including unusual items
-68.01M
-42.67M
-49.36M
-49.43M
EBT excluding unusual items
-68.01M
-42.67M
-49.36M
-49.43M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-68.01M
-42.67M
-49.36M
-49.43M
Net profit margin
-98.96%
-65.79%
-67.82%
-59.34%
Earnings per share
-0.78
-0.48
-0.55
-0.55
Interest and investment income
4.33M
3.56M
3.75M
5.59M
Interest expense
-9.59M
-11.85M
-12.68M
-12.98M
Net interest expenses
-5.26M
-8.28M
-8.93M
-7.38M
Depreciation and amortization charges
-
-
-
-
EBITDA
-62.54M
-34.20M
-39.99M
-41.89M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps